"Blood-Based Test for Colorectal Cancer Shows High Accuracy, Driving Surge in Exact Sciences Stock"
TL;DR
Exact Sciences stock surged to a seven-month high after Freenome revealed results of a study on its blood-based colon cancer test, which showed similar specificity but lower sensitivity compared to Exact's Cologuard. Analysts believe the results dispel concerns about blood-based tests replacing stool-based ones and expect Exact Sciences shares to trade on a fundamental basis going forward. Despite the stock's recent climb, Freenome could still improve its test's sensitivity for advanced adenomas.
- Exact Sciences Stock, A Cathie Wood's Play, Surges On Freenome's Pale Results Investor's Business Daily
- Opinion | Too few people are screened for colon cancer. This new test might help. The Washington Post
- Freenome Announces Topline Results for PREEMPT CRC® to Validate the First Version of its Blood-Based Test for the Early Detection of Colorectal Cancer PR Newswire
- New blood test shows high accuracy for colorectal cancer detection, study finds: ‘Not interchangeable’ Fox News
- Citi sees Exact Sciences shares climbing after rival's data disappoints Investing.com India
Want the full story? Read the original reporting
Read on Investor's Business Daily